Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Mileutis is a clinical-stage company focused on developing and commercializing natural and novel peptides for animal and human health.Mileutis' biopharmaceutical products have major market potential for chronic and infectious diseases. Mileutis' products will significantly reduce antibiotic use in human health and animal health management. Additionally, Mileutis' products benefit veterinary dairy management by increasing productivity.

Vascular Control Systems, Inc. develops medical devices. The company's services include, Doppler guided clamp for bilateral temporary occlusion of the uterine arteries and Doppler guided hemostat for blood loss control during open surgical procedures. Vascular Control Systems was founded in 1998 and is headquartered in San Juan Capistrano, CA.

BG Medicine, Inc. is a life sciences company. It engages in developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders. The firm distributes products such as BGM Galectin-3 to clinical laboratories, hospitals, and healthcare providers. The company was founded in February 2000 by Jan van der Greef and is headquartered in Foxboro, MA.

Biotest Pharma GmbH engages in the manufacture and distribution of medicinal and pharmaceutical products. The company is headquartered in Dreieich, Germany.

MirZyme Therapeutics is an innovative biopharmaceutical company focused on the development and commercialisation of tailored therapeutics to prevent preeclampsia and fetal growth restriction in pregnancy. MirZyme provides a stratified approach to identify patients who will develop preeclampsia and has developed first in class drugs to prevent preeclampsia and fetal growth restrictions. We have two therapeutic approaches, small molecules in capsules form and injectable synthetic miRNAs. MirZyme. One Test. One Pill. Save Two Lives.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Martek Biosciences Boulder Corp., a subsidiary of DSM-Firmenich AG, is a company headquartered in Boulder, CO. The firm produces and sells docosahexaenoic acid (DHA) products. Martek Biosciences Corp. acquired Martek Biosciences Boulder Corp. on April 25, 2002 for $95.49 million.

Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin).

DePuy Synthes Products, Inc. develops and markets medical products. It offers distal volar Radius, which is designed to treat distal radius fractures, dorsal endoplate, an invasive dorsal nail plate that provides fixed angle support and intramedullary locked fixation with a duplicate and reproducible surgical procedure, spatial subchondral support plate, which is used to treat proximal humeral fractures and Small Bone Fixation System, a percutaneous locked intramedullary nail system for metacarpals and the phalanges. The company was founded on June 22, 2004 and is headquartered in Wilmington, DE.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

Henan Huahuaniu Group Animal Husbandry Co., Ltd., established on 2004-12-09, Business scope includes breeding livestock and poultry(holstein cow)Production,Dairy Technical Services,Consulting and training.feed sales.import and export trade.(In the above range,The special examination and approval stipulated by the state shall be operated according to the valid date of the license approval)

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Société des Produits Nestlé SA engages in the manufacture and distribution of food, pharmaceutical, medical, and cosmetic products. The company was founded on December 15, 1936 and is headquartered in Vevey, France.

Beijing Zhongke Yonghe Medical Technology Co., Ltd., established on 2006-04-21, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services,Technical Training.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)